Sendero Wealth Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
VCM
VPM
Sendero Wealth Management's CRL Position: Q1 2026 in Review
Sendero Wealth Management increased its Charles River Laboratories (CRL) stake by 8.9% in Q1 2026, buying an estimated $395K and bringing the position to 26,039 shares worth $4.49M. The position accounts for 0.5% of the portfolio, ranked #38.
Sendero Wealth Management first reported a position in CRL in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.77M in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Sendero Wealth Management held 26,039 shares of Charles River Laboratories worth $4.49M as of Q1 2026.
- Sendero Wealth Management bought 2,132 Charles River Laboratories shares in Q1 2026, an estimated $395K.
- Charles River Laboratories made up 0.5% of Sendero Wealth Management's portfolio in Q1 2026, its #38 holding.
- Sendero Wealth Management first reported a position in Charles River Laboratories in Q2 2025 and has held it in 4 quarters since.
- Sendero Wealth Management's Charles River Laboratories position peaked at $4.77M in Q4 2025.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Sendero Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.